DK2611834T3 - Hurtig generering af antiidiotypiske antistoffer - Google Patents

Hurtig generering af antiidiotypiske antistoffer Download PDF

Info

Publication number
DK2611834T3
DK2611834T3 DK11755516.9T DK11755516T DK2611834T3 DK 2611834 T3 DK2611834 T3 DK 2611834T3 DK 11755516 T DK11755516 T DK 11755516T DK 2611834 T3 DK2611834 T3 DK 2611834T3
Authority
DK
Denmark
Prior art keywords
antibody
lgg2a
antibodies
idiotypic
mcd20
Prior art date
Application number
DK11755516.9T
Other languages
English (en)
Inventor
Robert J Dunn
Marilyn R Kehry
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Application granted granted Critical
Publication of DK2611834T3 publication Critical patent/DK2611834T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (18)

1. Ikke-terapeutisk fremgangsmåde til produktion af antiidiotypiske antistoffer omfattende: (a) co-administration til et ikke-humant dyr af et første antistof, der har en murin lgG2a isotype; og et andet antistof, der retter sig mod B-celler og har en murin lgG2a isotype; hvori det første og andet antistof har forskellige bindingsspecificiteter; hvori det andet antistof binder en B-celleoverflademarkør valgt fra gruppen bestående af CD19, CD20, CD21, CD22, CD40, CD45, IgM og IgD; og (b) isolering af de antiidiotypiske antistoffer som specifikt binder til det første antistof i trin (a).
2. Fremgangsmåde ifølge krav 1, yderligere omfattende: (c) produktion af en hybridomfusion af miltceller fra det immuniserede dyr og myelomfusionspartnere og isolering af de monoklonale antiidiotypiske antistoffer, som specifikt binder det første antistof.
3. Fremgangsmåde ifølge krav 2, hvori myelomfusionspartnerne er enten NS-1- eller SP2/0-celler.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1-3, hvori det ikke-humane dyr er modtageligt for autoimmun sygdom.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1-4, hvori det ikke-humane dyr er en mus.
6. Fremgangsmåde ifølge krav 5, hvori musen udtrykker lgh-1 b-allelen af lgG2a.
7. Fremgangsmåde ifølge krav 6, hvori musen er valgt fra gruppen bestående af: diabetisk uden fedme (NOD), resistent uden fedme (NOR), SJL, C.B-17 og C57BL/6.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1-7, hvori co-administrationen udføres sekventielt.
9. Fremgangsmåde ifølge krav 8, hvori de sekventielle co-administrationer gives som forstærkende administrationer.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1-7, hvori co-administrationen udføres samtidigt.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1-10, hvori det første og andet antistof administreres i et forhold på omkring 1:1.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1-10, hvori det første og andet antistof administreres i et forhold på omkring 1:2.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 1-10, hvori det første og andet antistof administreres i et forhold på omkring 1:4.
14. Fremgangsmåde ifølge et hvilket som helst af kravene 1-13, hvori det andet antistof binder CD20.
15. Fremgangsmåde ifølge krav 14, hvori det andet antistof er anti-mCD20-antistoffet 18B12.
16. Fremgangsmåde ifølge et hvilket som helst af kravene 1-15, hvori det første antistof specifikt binder et antigen valgt fra gruppen bestående af: alpha4-integrin, glycoprotein llb/llla, vaskulær endotelial vækstfaktor, epidermal vækstfaktor, komplement C5-protein, ErbB2, CD3-receptor, CD11a, CD20, CD23, CD25, CD33, CD52, BCMA, CD40, lymphotoxin a, lymphotoxin αιβ2, LIGHT, TWEAK, CD154, VLA4, EGFR, IGF1R, CD169, IL-6, IL-23, TNF- a, neonatal Fc-receptor (FcRn), BDCA-2, DCIR, DR6 (dødsreceptor 6), LINGO-1, Tyro3, RON receptortyrosinkinase, DDR1 (discoidin domænereceptor 1), HER3, FN14, VEGF og CD103.
17. Fremgangsmåde ifølge krav 16, hvori det første antistof specifikt binder CD20.
18. Fremgangsmåde ifølge krav 17, hvori det første antistof omfatter de variable domæner i rituximab.
DK11755516.9T 2010-09-01 2011-08-31 Hurtig generering af antiidiotypiske antistoffer DK2611834T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37908910P 2010-09-01 2010-09-01
PCT/US2011/050001 WO2012030982A1 (en) 2010-09-01 2011-08-31 Rapid generation of anti-idiotypic antibodies

Publications (1)

Publication Number Publication Date
DK2611834T3 true DK2611834T3 (da) 2018-06-18

Family

ID=44645832

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11755516.9T DK2611834T3 (da) 2010-09-01 2011-08-31 Hurtig generering af antiidiotypiske antistoffer

Country Status (7)

Country Link
US (1) US10150817B2 (da)
EP (1) EP2611834B1 (da)
JP (1) JP5985481B2 (da)
AU (1) AU2011295968B2 (da)
DK (1) DK2611834T3 (da)
IL (1) IL224974A (da)
WO (1) WO2012030982A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371396B2 (en) 2012-06-15 2016-06-21 Sinomab Bioscience Limited Anti-CD22 anti-idiotypic antibodies and uses thereof
GB201216002D0 (en) * 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
US10214593B2 (en) 2013-04-02 2019-02-26 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-c-MET antibody
EP2787008B1 (en) * 2013-04-02 2019-09-04 Samsung Electronics Co., Ltd. Anti-idiotype antibody against anti-C-met antibody
WO2015117229A1 (en) 2014-02-07 2015-08-13 Mcmaster University Trifunctional t cell-antigen coupler and methods and uses thereof
CA3078637A1 (en) 2017-10-12 2019-04-18 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
EP3813878A4 (en) * 2018-06-14 2022-03-16 2seventy bio, Inc. CAR ANTI-BCMA ANTIBODIES, CONJUGATES AND METHODS OF USE
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
CN115916817A (zh) * 2019-12-06 2023-04-04 朱诺治疗学股份有限公司 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
EP4121109A4 (en) * 2020-03-18 2024-04-24 The Rockefeller University ANTIBODY GENE EDITING IN B CELLS AND CO-EXPRESSION OF A CARGO PROTEIN
US20220064335A1 (en) * 2020-08-25 2022-03-03 Crispr Therapeutics Ag Anti-idiotype antibodies targeting anti-bcma chimeric antigen receptor
AU2022283819A1 (en) 2021-06-01 2024-01-04 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
WO2023220647A1 (en) 2022-05-11 2023-11-16 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614610A (en) 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
PT89107A (pt) * 1987-11-30 1989-11-30 Idec Pharma Corp Metodo e meios para a seleccao de anticorpos anti-idiotipos e seu uso para o diagnostico, monitorizacao, tratamento e/ou prevencao de doencas cancerosas, da autoimunidade ou infecciosas
AU1025692A (en) 1991-02-06 1992-08-13 Ciba-Geigy Ag Novel chimeric antiidiotypic monoclonal antibodies
ATE160786T1 (de) 1991-04-03 1997-12-15 American Cyanamid Co Wachstumsstimulierung durch antiidiotypische antikörper erzeugt gegen einen für schweinewachstumshormon spezifischen antikörper
CZ286547B6 (cs) * 1992-05-22 2000-05-17 Novartis Ag Monoklonální protilátky a jejich použití
AU5605398A (en) * 1996-12-11 1998-07-03 University Of Florida Novel methods and compositions for treatment of autoimmune diseases
US20020102264A1 (en) * 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
US20030072762A1 (en) 2001-08-03 2003-04-17 Van De Winkel Jan G. J. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance Fc receptor-mediated immunotherapies
EP1511772B1 (en) * 2002-05-28 2011-11-23 Omrix Biopharmaceuticals Inc. Method for obtaining anti-idiotype antibodies
US20070136826A1 (en) 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof

Also Published As

Publication number Publication date
EP2611834B1 (en) 2018-03-07
JP5985481B2 (ja) 2016-09-06
AU2011295968A1 (en) 2013-03-21
JP2013538812A (ja) 2013-10-17
IL224974A (en) 2017-10-31
EP2611834A1 (en) 2013-07-10
WO2012030982A1 (en) 2012-03-08
AU2011295968B2 (en) 2017-01-05
US10150817B2 (en) 2018-12-11
US20130330323A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
DK2611834T3 (da) Hurtig generering af antiidiotypiske antistoffer
JP6923658B2 (ja) 抗ｃｄ４７抗体およびその使用
US11655296B2 (en) Anti-CD47 antibody and use thereof
EP3237004B1 (en) Predicting outcome of treatment with an anti-alpha4 beta7 integrin antibody
TWI432452B (zh) 針對ｈｅｒ-３之抗體類及其用途
MX2014009043A (es) Anticuerpos anti-ige y sus metodos de uso.
WO2020228604A1 (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
US20190209701A1 (en) Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
US20220403022A1 (en) Anti-TIGIT Antibodies and Uses Thereof
US20230078601A1 (en) Anti-mullerian hormone receptor 2 antibodies and methods of use
MX2015000730A (es) Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja.
JP2019519544A (ja) 炎症性腸疾患を治療する方法
US20230242646A1 (en) Humanized Anti-Human CD89 Antibodies and Uses Thereof
US20240165252A1 (en) Antibody-drug conjugate and medical use thereof
WO2023220750A1 (en) Compositions and methods for treating lupus nephritis
WO2023130001A1 (en) Compositions and methods for treating huntington's disease